CN104000944B - A kind of health products or pharmaceutical composition and its production and use with warming kidney to invigorate yang - Google Patents
A kind of health products or pharmaceutical composition and its production and use with warming kidney to invigorate yang Download PDFInfo
- Publication number
- CN104000944B CN104000944B CN201410265141.6A CN201410265141A CN104000944B CN 104000944 B CN104000944 B CN 104000944B CN 201410265141 A CN201410265141 A CN 201410265141A CN 104000944 B CN104000944 B CN 104000944B
- Authority
- CN
- China
- Prior art keywords
- health products
- pharmaceutical composition
- group
- dysfunction
- cloves
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a kind of health products or the pharmaceutical composition with warming kidney to invigorate yang, its bulk drug is containing, for example the flavour of a drug of lower weight: agate coffee 1 ~ 1.5 part, cloves 1 part, matrimony vine 1 ~ 1.5 part.Present invention also offers preparation method and the purposes of said composition.Test shows, health products of the present invention or pharmaceutical composition have good tonifying kidney and strengthening yang effect, can effectively improve buck sex dysfunction, for clinical application provides new selection.
Description
Technical field
The present invention relates to a kind of health products or pharmaceutical composition and its production and use with warming kidney to invigorate yang.
Background technology
In recent years, due to the impact of the factors such as psychology, environment, society, in world wide, the fecundity of the couple at child-bearing age is in downward trend year by year, and this wherein most of reason because male fecundity decline causes.Male sterility, namely reproductive system dysfunction mainly contains the reason of two aspects, first semen quality low, and it two is male sexual disfunctions.
Male sexual disfunction is male sterility reason important clinically, and erectile dysfunction (impotence) is main male sexual disfunction.In the whole sample of MMAS, the U.S. 40-70 year male sex the impotence incidence of disease be 52%, China also has more than one hundred million people to suffer from impotence in various degree, and the incidence of disease increases with the age and increases.Along with the increase of social pressures, also there is obvious rejuvenation trend in the generation of impotence, and the symptom of obvious impotence has also appearred in the male sex of many 20-30 year age brackets.
Chinese medicine has advantageous advantage in treatment male sterility, and the traditional Chinese medical science thinks that kidney is congenital dirty, reproduction this, if deficiency of kidney-QI, can male reproductive function be had influence on.Under Basic Theories of Chinese Medicine instructs, Chinese medicine reasonable formula uses surface symptoms such as can not only improving impotence, premature ejaculation, erection heavily fortified point; Can also comprehensive adjustment reproductive system function, fundamentally improve without symptoms such as essence, few essence, dead essences, inside and outside conditioning, treats both principal and secondary aspect of disease.Patent application: 103100025A, discloses a kind of pharmaceutical composition for kidney-reinforcing Yang-strengthening: ginseng 5 ~ 10 parts, the Radix Astragali 2.5 ~ 5 parts, Psoralea corylifolia (salt stir-fry) 2.5 ~ 5 parts, Morinda officinalis (system) 2.5 ~ 5 parts, saline cistanche 2.5 ~ 5 parts, Fructus Corni (system) 2.5 ~ 5 parts, the fruit of Chinese wolfberry 2.5 ~ 5 parts, raspberry 2.5 ~ 5 parts, prepared fleece flower root 2.5 ~ 5 parts, the bark of eucommia (salt system) 2.5 ~ 5 parts, Chinese cassia tree 2.5 ~ 5 parts, the seed of Chinese dodder 2.5 ~ 5 parts, Chinese yam 2.5 ~ 5 parts, fructus amomi 2.5 ~ 5 parts, the bighead atractylodes rhizome 2.5 ~ 5 parts, the tuber of dwarf lilyturf 2.5 ~ 5 parts, asparagus fern 2.5 ~ 5 parts, 2.5 ~ 5 parts, the fruit of Chinese magnoliavine, prepared rhizome of rehmannia 2.5 ~ 5 parts, chrysanthemum 2.5 ~ 5 parts, golden cypress (salt stir-fry) 2.5 ~ 5 parts, plantain seed (salt stir-fry) 2.5 ~ 5 parts, the seed of Oriental arborvitae 2.5 ~ 5 parts, polygala root (system) 2.5 ~ 5 parts, has clear and definite tonifying kidney and strengthening yang, blood-enrich, controlling nocturnal emission with astringent drugs antidiarrheal, improve immunity of organisms, significantly improve male's sexual, improvement quality of life, and can be used for prevention and therapy impotence, the sex dysfunctions such as premature ejaculation, have good clinical effectiveness.Cynomorium songaricum capsule for tonifying kidney, be prepared from primarily of the medicine such as cynomorium songaricum, thizoma curculiginis, Morinda officinalis, Radix Angelicae Sinensis, frutus cnidii, saline cistanche, semen allii tuberosi, the fruit of Chinese magnoliavine, red ginseng, pizzle, dog kidney, pilose antler, black suitable sheet, Chinese cassia tree, fennel seeds, actinolite, Chinese prickly ash, the seed of Chinese dodder, the bark of eucommia, tonifying kidney and strengthening yang, replenishing essence is admittedly true, for the disease such as impotence, seminal emission, premature ejaculation that kidney-yang deficiency or kidney-yin deficiency cause.
Although at present can tonifying kidney and strengthening yang, improve male sexual disfunction prescription numerous, its prescription taste of traditional Chinese medicine quantity is many, and cost is high, and is unfavorable for the protection to Chinese medicine plant variety.
If a kind of flavour of a drug can be provided less, and drug activity good new drug, better selection will be provided for patient.
Summary of the invention
The object of the present invention is to provide a kind of health products or the pharmaceutical composition with warming kidney to invigorate yang.Another object of the present invention is to preparation method and purposes that these health products or pharmaceutical composition are provided.
The invention provides a kind of health products or the pharmaceutical composition with warming kidney to invigorate yang, its bulk drug is containing, for example the flavour of a drug of lower weight: agate coffee 1 ~ 1.5 part, cloves 1 part, matrimony vine 1 ~ 1.5 part.
Further, its bulk drug is containing, for example the flavour of a drug of lower weight: agate coffee 1.5 parts, cloves 1 part, matrimony vine 1.5 parts.
Further, described bulk drug is made up of the flavour of a drug of following weight proportion: agate coffee 1 ~ 1.5 part, cloves 1 part, matrimony vine 1 ~ 1.5 part.
Find in the present invention's test, after adopting different consumptions to carry out compatibility use three taste medicinal materials, its drug activity there occurs marked change, wherein best with drug effect during following proportioning, is even better than positive drug cynomorium songaricum capsule for tonifying kidney: agate coffee 1.5 parts, cloves 1 part, matrimony vine 1.5 parts.
In the present invention, described agate coffee (LepidiummeyeniiWalp): be the dry rhizome of Cruciferae (Cruciferae) Lepidium (Lepidium) agate coffee; Cloves: be the dry flower of plant clove of myrtaceae EugeniacaryophyllataThunb.; Matrimony vine: be the dry mature fruit of plant of Solanaceae lycium barbarum LyciumbarbarumL..
Wherein, it be by the medicinal powder of bulk drug, water extract or/and ethanol extract is active component, add pharmaceutically conventional auxiliary material or/and the formulation that is prepared from of complementary composition.
Further, described ethanol extract is 50% ~ 70%v/v ethanol extract.
Water extract or be used as medicine with medicinal powder is all Chinese medicine tradition occupation modes, and after water extraction, because the soluble end of water is wide, can, by most of active ingredient stripping, medicine is more easily absorbed by the body, onset be faster, the form of medication such as such as decoction; Be used as medicine with former powder, the surface area of medicinal powder is larger, also active ingredient absorption in vivo in medicinal material is conducive to, but medicinal material un-extracted, active ingredient still needs stripping in vivo to absorb again, and the relative water extract of its onset is comparatively slow, but also weakens the toxicity that in medicinal material, harmful components cause human body simultaneously, be suitable for long-term taking, as former powder is prepared into the form of medication such as pill.At present in pharmacy procedure, ethanol extracts medicine as solvent, also be one of the most common extracting mode, ethanol is semi-polarity solvent, solubility property circle is between polarity and non-polar solven, some composition water miscible can be dissolved, also some compositions that non-polar solven dissolves can be dissolved, usually decocting is replaced with alcohol extract, thus avoid the stripping of a large amount of invalid components, improve concentration and the extraction efficiency of active ingredient, but comparatively water is expensive for the price of ethanol, in the large production of modern pharmaceutical industry, each side factor determination extraction process can be considered.
Pharmaceutically acceptable auxiliary material of the present invention, refer to the material be included in addition to the active ingredient (s in formulation, include but are not limited to filler (diluent), lubricant (glidant or antitack agent), dispersant, wetting agent, adhesive, conditioning agent, solubilizer, antioxidant, bacteriostatic agent, emulsifying agent, disintegrant etc.Adhesive comprises syrup, Arabic gum, gelatin, sorbierite, tragacanth, cellulose and its derivates (as microcrystalline cellulose, sodium carboxymethylcellulose, ethyl cellulose or HPMC etc.), gelatine size, syrup, starch slurry or polyvinylpyrrolidone etc.; Filler comprises lactose, Icing Sugar, dextrin, starch and derivative thereof, cellulose and its derivates, inorganic calcium salt (as calcium sulfate, calcium phosphate, calcium monohydrogen phosphate, precipitated calcium carbonate etc.), sorbierite or glycine etc.; Lubricant comprises superfine silica gel powder, dolomol, talcum powder, aluminium hydroxide, boric acid, hydrogenated vegetable oil, polyethylene glycol etc.; Disintegrant comprises starch and derivative (as sodium carboxymethyl starch, Explotab, pregelatinized starch, modified starch, hydroxypropul starch, cornstarch etc.), polyvinylpyrrolidone or microcrystalline cellulose etc.; Wetting agent comprises lauryl sodium sulfate, water or alcohol etc.; Antioxidant packages is containing sodium sulfite, sodium hydrogensulfite, sodium pyrosulfite, dibutyl benzoic acid etc.; Bacteriostatic agent comprises 0.5% phenol, 0.3% cresols, 0.5% anesin etc.; Conditioning agent comprises hydrochloric acid, citric acid, potassium hydroxide (sodium), sodium citrate and buffer (comprising phosphoric acid dioxy sodium and sodium hydrogen phosphate) etc.; Emulsifier package containing Tween-80, do not have that sour sorb is smooth, pluronic gram F-68, lecithin, Fabaceous Lecithin etc.; Solubilizer comprises Tween-80, bile, glycerine etc.
Described pharmaceutically acceptable complementary composition, it has certain physiologically active, but adding of this composition can not change above-mentioned health products or the leading position of pharmaceutical composition in treatment of diseases, and only play auxiliary effect, these auxiliary effects are only the utilizations to this composition known activity, are the usual adjuvant treatment modality of field of medicaments.
Wherein, described formulation is through gastrointestinal absorption formulation.Such as, tablet, powder, pill, capsule, granule, vina or oral liquid.
Present invention also offers the preparation method of above-mentioned health products or pharmaceutical composition, it comprises following operating procedure:
(1) by proportioning weighting raw materials;
(2) after cloves extracts volatile oil, the dregs of a decoction and all the other medicinal materials add alcohol extract, and collect alcohol extract, the dregs of a decoction are extracting in water again, collect Aqueous extracts, alcohol extract, Aqueous extracts and volatile oil are merged preparation, to obtain final product.
Further, described concentration of alcohol is 50% ~ 70%v/v.
Further, the concrete operations of alcohol extract are: refluxing extraction 3 times, each 1 ~ 3 hour;
The concrete operations that water extraction is got are: water boiling and extraction 3 times, each 1 ~ 3 hour.
Present invention also offers above-mentioned health products or pharmaceutical composition preparing tonifying kidney and strengthening yang, improve buck sex dysfunction or improve the purposes in the health products of fecundity or medicine.
Further, described sex dysfunction refers to the weak dysfunction of erectile dysfunction, dysaphrodisia, sexual dysfunction, defective ejaculation, property sensory disturbance or penis.
Wherein, described animal is mammal.
Further, described mammal is primate, artiodactylous animals or rodent.
Further, described primate refers to the mankind.
Test shows, health products of the present invention or pharmaceutical composition have good tonifying kidney and strengthening yang effect, can effectively improve buck sex dysfunction, for clinical application provides new selection.
Obviously, according to foregoing of the present invention, according to ordinary technical knowledge and the means of this area, not departing under the present invention's above-mentioned basic fundamental thought prerequisite, the amendment of other various ways, replacement or change can also be made.
Below by way of the form of specific embodiment, foregoing of the present invention is described in further detail again.But this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following embodiment.All technology realized based on foregoing of the present invention all belong to scope of the present invention.
Detailed description of the invention
Embodiment 1
[prescription] raw material: agate coffee 150g, cloves 100g, matrimony vine 150g
Auxiliary material: microcrystalline cellulose 200g starch 150g sodium carboxymethylcellulose 50g
[method for making] gets cloves, adds water appropriate, sends out extraction volatile oil with steam distillation, after the dregs of a decoction and all the other two tastes add alcohol immersion 30min, heating is extracted for several times, filters, merge extract, the dregs of a decoction again boiling for several times, filter, merge twice filtrate, be evaporated to suitable density, after letting cool, add volatile oil, add auxiliary materials and mixing after mixing, cross 80 mesh sieves after frozen drying, mix, add 95% ethanol softwood, 16 order nets are granulated; Whole grain after frozen drying, then adds dolomol 50g, and mixing, is pressed into 1000, dressing and get final product.
Embodiment 2
[prescription] raw material: agate coffee 150g, cloves 100g, matrimony vine 150g
Auxiliary material: microcrystalline cellulose 280g lactose 160g
[method for making] gets cloves, adds water appropriate, sends out extraction volatile oil with steam distillation, after the dregs of a decoction and all the other two tastes add alcohol immersion 30min, heating is extracted for several times, filters, merge extract, the dregs of a decoction again boiling for several times, filter, merge twice filtrate, be evaporated to suitable density, after letting cool, add volatile oil, add auxiliary materials and mixing after mixing, cross 80 mesh sieves after frozen drying, mix, add 95% ethanol softwood, 16 order nets are granulated; After frozen drying, whole grain, encapsulated, makes 1000 altogether.
Embodiment 3
[prescription] raw material: agate coffee 150g, cloves 100g, matrimony vine 150g
Auxiliary material: lactose 200g starch 150g Steviosin 50g
[method for making] gets cloves, adds water appropriate, sends out extraction volatile oil with steam distillation, after the dregs of a decoction and all the other two tastes add alcohol immersion 30min, heating is extracted for several times, filters, merge extract, the dregs of a decoction again boiling for several times, filter, merge twice filtrate, be evaporated to suitable density, after letting cool, add volatile oil, add auxiliary materials and mixing after mixing, cross 80 mesh sieves after frozen drying, mix, add 95% ethanol softwood, 16 order nets are granulated; Whole grain after frozen drying, pack sealing, makes 1000 bags altogether.
Beneficial effect of the present invention is illustrated below by way of test example.
Test example 1
1. materials and methods
1.1 prescription medicinal materials and base former
(1) agate coffee (LepidiummeyeniiWalp): be the dry rhizome of Cruciferae (Cruciferae) Lepidium (Lepidium) agate coffee.
(2) cloves: be the dry flower of plant clove of myrtaceae EugeniacaryophyllataThunb..
(3) matrimony vine: be the dry mature fruit of plant of Solanaceae lycium barbarum LyciumbarbarumL..1.2 process for preparing medicine
(1) compound dose 1. group: agate coffee 29g, cloves 22g, matrimony vine 28g.
(2) compound dose 2. group: agate coffee 20g, cloves 15g, matrimony vine 20g.
(3) compound dose 3. group: agate coffee 15g, cloves 10g, matrimony vine 15g.
(4) compound dose 4. group: agate coffee 7g, cloves 5g, matrimony vine 7g.
(5) compound dose 5. group: agate coffee 1g, cloves 1g, matrimony vine 1g.
According to dosage organize prescription ratio respectively and take medicinal material, after cloves collects volatile oil with steam distillation, it is appropriate that the dregs of a decoction and all the other two taste medicinal materials add 50% ~ 70% concentration ethanol, refluxing extraction 3 times, each 1 ~ 3 hour, filters, collect filtrate, be evaporated to proper volume.The dregs of a decoction add suitable quantity of water and decoct 3 times, decoct 1 ~ 3h at every turn, filter, and collect filtrate, are evaporated to proper volume, merge twice concentrate, add volatile oil and mix after letting cool, obtain pharmacology test sample.
1.3 animal used as test
(1) KM mouse, male, body weight 18.5 ~ 22.5g.
(2) SD rat, male, body weight 180 ~ 220g.
1.4 laboratory apparatus, reagent
(1) ELIASA, electronic balance etc.
(2) penicillin, streptomysin, physiological saline, ethanol for disinfection etc.
1.5 positive drug
(1) cynomorium songaricum capsule for tonifying kidney.
1.6 modeling medicines
Hydrocortisone.
1.7 kit
Testosterone (T) Elisa detection kit, cortisol (Cortisol) Elisa detection kit.
2. drug efficacy study
2.1 impacts on the Mouse Kidney deficiency of yang
2.1.1 experimental technique
Be divided at random by body weight after all mouse adaptability feeds 1 week: normal group, model group, positive group (cynomorium songaricum capsule for tonifying kidney group), compound dose of the present invention 1. ~ 5. group, often organize 10.Its positives group starts according to dosage from experimental day by each experimental group, administering mode gives relative medicine, its positives group gives cynomorium songaricum capsule for tonifying kidney by 20g crude drug/kg dosage gavage, the each dosage of compound of the present invention gives different ratio compound extract by 10g crude drug/kg dosage gavage, normal group and model group gavage equal-volume pure water, continuous 10 days.Test the 6th day, except normal group, all the other respectively organize mouse by 25mgkg
-1dosage lumbar injection hydrocortisone normal saline solution, continuous 4 days, normal group mouse peritoneal injection equal-volume physiological saline.Test the 11st day, each experimental mice eye socket gets blood, collects, 3000rmin with 1.5mlEP pipe
-1centrifugal 10min, collects supernatant to be measured.On aseptic working platform, take each experimental mice testis and seminal vesicle, bloodstain cleaned by physiological saline.
2.1.2 Testing index
(1) hormonal readiness: Elisa method measures each experimental mice serum testosterone (T) and cortisol (Cortisol) level.
(2) main sexual organ weight coefficient: take each experimental mice testis and seminal vesicle gross weight, computational organ weight coefficient [organ weight (g)/body weight (g)].
2.1.3 statistical method
SPSS19.0 statistical software is adopted to carry out statistical analysis.Data represent with Mean ± SD, compare and adopt One-WayANOVA inspection between multisample mean, and variance then adopts LSD inspection together, and heterogeneity of variance then adopts Tamhane ' sT2 to check.
2.1.4 experimental result
2.1.4.1 on the impact of mice with kidney-yang deficiency PBC
The results are shown in Table 1.
The each experimental mice serum T of table 1 and Cortisol level
Note: compare with model group, * P<0.05, * * P<0.01; Compare with positive group,
Δp<0.05,
Δ Δp<0.01.
As shown in Table 1, compare with model group, compound each dosage group mice serum T level all has remarkable rising (P<0.05), dosage 3. with dosage 4. group have extremely significantly raise (P<0.01).Compare with positive group, 4. 3. dosage organize mouse peripheral blood liquid quantity of leucocyte with dosage all have remarkable rising (P<0.05); Compare with model group, compound each dosage group mice serum Cortisl level all has remarkable rising (P<0.05).Compare with positive group, 3., 4., 5. dosage organize mice serum Cortisl level all remarkable rising (P<0.05).Show that each dosage group of compound of the present invention all has rising effect in various degree to mice with kidney-yang deficiency testosterone and cortisol.
2.1.4.2 on the impact of mice with kidney-yang deficiency sexual organ weight
The results are shown in Table 2.
Table 2 each experimental mice sexual organ weight coefficient
Note: compare with model group, * P<0.05, * * P<0.01; Compare with positive group,
Δp<0.05,
Δ Δp<0.01.
As shown in Table 2, compare with model group, compound each dosage group mouse sexual organ weight coefficient all enlarges markedly (P<0.05).Compare with positive group, 3. dosage organized mouse sexual organ weight coefficient and enlarged markedly (P<0.05).
2.2 impacts on male rat telotism and mating ability
2.1.1 experimental technique
Be divided at random by body weight after SD rat adaptability feeds 1 week: control group, positive group (cynomorium songaricum capsule for tonifying kidney group), compound dose 1. ~ 5. group, often organize 10.Its positives group starts according to dosage from experimental day by each experimental group, administering mode gives relative medicine, its positives group gives cynomorium songaricum capsule for tonifying kidney by 12g/kg dosage gavage, the each dosage of compound gives different ratio compound extract by 6g/kg dosage gavage, control group gavage equal-volume pure water, continuous 15 days.Test 2h after administration in the 15th day, the stimulating electrode of egersimeter is positioned over rat penis position, gives surface element electro photoluminescence, current strength 4mA, cycle 50ms, pulsewidth lms, train of pulse .10.Record to the telotism time from stimulation, this time is rat eclipse period of penile erection.
After the administration of male rat last, male rat list is only put into cage and make its 5min that conforms, then put into 1 female mouse.Start to record following index: 1. drop into from female mouse, male mouse catches the time (catching incubation period) of female mouse for the first time; 2. in 20min, male mouse flutters the number of times catching female mouse; 3. drop into from female mouse, the time (ejaculation latency) of male mouse first time ejaculation.
2.2.2 Testing index
Each experimental group rat erect incubation period, catch incubation period, catch number of times and ejaculation latency.
2.2.3 statistical method
SPSS19.0 statistical software is adopted to carry out statistical analysis.Data represent with Mean ± SD, compare and adopt One-WayANOVA inspection between multisample mean, and variance then adopts LSD inspection together, and heterogeneity of variance then adopts Tamhane ' sT2 to check.
2.2.4 experimental result
Result is respectively in table 3 and table 4.
The each experimental group rat of table 3 erects incubation period and catch incubation period
Note: compare with model group, * P<0.05, * * P<0.01; Compare with positive group,
Δp<0.05,
Δ Δp<0.01.
As shown in Table 3, compare with control group, compound each dosage group rat erects all has remarkable shortening (P<0.05) incubation period, dosage 3. group has extremely significantly shortening (P<0.01), simultaneously, compound each dosage group rat catches all has remarkable shortening (P<0.05) incubation period, shows that each dosage of compound of the present invention all can promote rat telotism, improves rat sexual desire and hopes.
The each experimental group rat of table 4 catches number of times and ejaculation latency
Note: compare with model group, * P<0.05, * * P<0.01; Compare with positive group,
Δp<0.05,
Δ Δp<0.01.
As shown in Table 4, compare with control group, compound each dosage group rat catches number of times all to be had and significantly increases (P<0.05); Meanwhile, compound each dosage group rat ejaculation latency all has significant prolongation (P<0.05), shows that each dosage of compound of the present invention all can improve rat sexual desire and hope, prolong rats mating time.
3. conclusion
Health products of the present invention or pharmaceutical composition have good establishing-Yang and the effect of improvement dysfunction, and activity is better than positive drug.
Claims (11)
1. there is health products or the pharmaceutical composition of warming kidney to invigorate yang, it is characterized in that: described health products or pharmaceutical composition are made up of the bulk drug of following weight proportion: agate coffee 1.5 parts, cloves 1 part, matrimony vine 1.5 parts.
2. health products according to claim 1 or pharmaceutical composition, is characterized in that: it be by the medicinal powder of bulk drug, water extract or/and ethanol extract is active component, add pharmaceutically conventional auxiliary material or/and the formulation that is prepared from of complementary composition.
3. health products according to claim 2 or pharmaceutical composition, is characterized in that: described formulation is through gastrointestinal absorption formulation.
4. the preparation method of health products or pharmaceutical composition described in claims 1 to 3 any one, is characterized in that: it comprises following operating procedure:
(1) by proportioning weighting raw materials;
(2) after cloves extracts volatile oil, the dregs of a decoction and all the other medicinal materials add alcohol extract, and collect alcohol extract, the dregs of a decoction are extracting in water again, collect Aqueous extracts, alcohol extract, Aqueous extracts and volatile oil are merged preparation, to obtain final product.
5. preparation method according to claim 4, is characterized in that: described concentration of alcohol is
50％～70％v/v。
6. preparation method according to claim 4, is characterized in that: the concrete operations of alcohol extract are: refluxing extraction 3 times, each 1 ~ 3 hour; The concrete operations that water extraction is got are: water boiling and extraction 3 times, each 1 ~ 3 hour.
7. health products described in claims 1 to 3 any one or pharmaceutical composition preparing tonifying kidney and strengthening yang, improve buck sex dysfunction or improve the purposes in the health products of fecundity or medicine.
8. purposes according to claim 7, is characterized in that: described sex dysfunction refers to the weak dysfunction of erectile dysfunction, dysaphrodisia, sexual dysfunction, defective ejaculation, property sensory disturbance or penis.
9. purposes according to claim 7, is characterized in that: described animal is mammal.
10. purposes according to claim 9, is characterized in that: described mammal is primate, artiodactylous animals or rodent.
11. purposes according to claim 10, is characterized in that: more preferably, described primate refers to the mankind.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410265141.6A CN104000944B (en) | 2014-06-13 | 2014-06-13 | A kind of health products or pharmaceutical composition and its production and use with warming kidney to invigorate yang |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410265141.6A CN104000944B (en) | 2014-06-13 | 2014-06-13 | A kind of health products or pharmaceutical composition and its production and use with warming kidney to invigorate yang |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104000944A CN104000944A (en) | 2014-08-27 |
| CN104000944B true CN104000944B (en) | 2016-03-16 |
Family
ID=51362032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410265141.6A Active CN104000944B (en) | 2014-06-13 | 2014-06-13 | A kind of health products or pharmaceutical composition and its production and use with warming kidney to invigorate yang |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104000944B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104522815B (en) * | 2015-01-14 | 2016-07-06 | 三株福尔制药有限公司 | A kind of probiotics fermention maca composition and its preparation method and application |
| CN105770184A (en) * | 2016-04-05 | 2016-07-20 | 上海育生堂科技有限公司 | Pharmaceutical composition for treating impotence and premature ejaculation |
| CN108795671A (en) * | 2018-07-04 | 2018-11-13 | 云南省药物研究所 | A kind of production method of rose maca healthy wine |
| CN115192667A (en) * | 2022-08-26 | 2022-10-18 | 深圳市双百康医药科技有限公司 | Traditional Chinese medicine composition for improving sexual function and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101455367A (en) * | 2008-12-31 | 2009-06-17 | 云南省农业科学院高山经济植物研究所 | Lepidium meyenii Walp. health products |
| CN102579547A (en) * | 2012-03-26 | 2012-07-18 | 张丽琴 | Method for extracting active ingredients of maca |
| CN102716263A (en) * | 2012-07-12 | 2012-10-10 | 云南滇隆制药有限公司 | Maca, ginseng and medlar composition and application thereof |
| CN103750327A (en) * | 2014-01-27 | 2014-04-30 | 杨子驿 | Strong and healthy nutritious food suitable for men |
-
2014
- 2014-06-13 CN CN201410265141.6A patent/CN104000944B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101455367A (en) * | 2008-12-31 | 2009-06-17 | 云南省农业科学院高山经济植物研究所 | Lepidium meyenii Walp. health products |
| CN102579547A (en) * | 2012-03-26 | 2012-07-18 | 张丽琴 | Method for extracting active ingredients of maca |
| CN102716263A (en) * | 2012-07-12 | 2012-10-10 | 云南滇隆制药有限公司 | Maca, ginseng and medlar composition and application thereof |
| CN103750327A (en) * | 2014-01-27 | 2014-04-30 | 杨子驿 | Strong and healthy nutritious food suitable for men |
Non-Patent Citations (1)
| Title |
|---|
| 中药对肾阳虚模型作用的研究进展;蔡少峰等;《江西中医学院学报》;20070310(第01期);第93-94页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104000944A (en) | 2014-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1245187C (en) | Medicine for treating eye disease caused by visceral disease | |
| CN103990081B (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating infant jaundice | |
| CN104000197B (en) | A kind of health products or pharmaceutical composition and its production and use of fatigue-relieving | |
| CN104000944B (en) | A kind of health products or pharmaceutical composition and its production and use with warming kidney to invigorate yang | |
| CN103263531B (en) | Chinese medicine composition for treating prosopalgia and preparation method thereof | |
| CN103520293A (en) | Oral traditional Chinese medicine for improving and treating constipation | |
| CN105287812B (en) | A kind of medical composition and its use for treating irritable bowel syndrome | |
| CN103948742B (en) | Pharmaceutical composition for improving male animal sexual dysfunction | |
| CN103705860B (en) | A kind of Chinese medicine composition for the treatment of infant jaundice and preparation method thereof | |
| CN103989750B (en) | A pharmaceutical composition boosting animal immunity and a preparation method thereof | |
| CN103623109B (en) | Traditional Chinese medicine composition for treating ischemic cerebrovascular disease and preparation method thereof | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| WO2016041462A1 (en) | Pharmaceutical composition for treating snoring, preparation method therefor and use thereof | |
| CN104587342A (en) | Medicinal liquor suitable for being drunk by patients with hyperthyroidism and preparation process thereof | |
| CN1272047C (en) | Medicine for invigorating liver and kidney to treat dryness of large intestine and constipation | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN106474297A (en) | Improve pharmaceutical composition of gerontal patient's postoperative cognition disorders and preparation method thereof | |
| CN105727237A (en) | Folium artemisiae argyi-containing pharmaceutical composition for treating amenorrhea | |
| CN108175818B (en) | Traditional Chinese medicine composition for treating glaucoma and preparation method and application thereof | |
| CN101683461A (en) | Application of a traditional Chinese medicine composition in preparation of medicament for inhibiting oxidation damage | |
| CN105853796A (en) | Medicine composition for treating habitual abortion | |
| CN105362784A (en) | Medicine composition for treating hysteromyoma and preparation method thereof | |
| CN105535658A (en) | Traditional Chinese medicine composition for treating dental ulcer and preparation method thereof | |
| CN104784646A (en) | Pharmaceutical composition for treating infantile hernia and preparation method of pharmaceutical composition | |
| CN103933097A (en) | Pharmaceutical composition for strengthening animal immunity and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210107 Address after: No.802, 789 Xueqian East Road, Wuxi City, Jiangsu Province, 214000 Patentee after: Wuxi baoyuankang Health Technology Co.,Ltd. Address before: Room 206, Building 5, Gaopeng Avenue, Chengdu High-tech Zone, Sichuan 610041 Patentee before: CHENGDU BAICAO HEJI TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right |